Alnylam updates increase confidence in upcoming data, says Piper Jaffray After Alnylam presented new data on its Phase II study of patisiran in patients with Familial Amyloidotic Polyneuropathy, PiperJaffray says that the data increases its optimism about the outlook for a Phase III trial of the treatment in 2016. The firm keeps an Overweight rating on the stock.
Alnylam transthyretin amyloidosis treatment designated for FDA orphan status Alnylam's revusiran was designated by the FDA for orphan drug status as a treatment of transthyretin amyloidosis. Reference Link
UBS to hold a conference Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link